Universal Beteiligungs und Servicegesellschaft mbH Makes New $906,000 Investment in InMode Ltd. (NASDAQ:INMD)

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH has acquired a new stake in InMode Ltd., purchasing 51,054 shares valued at approximately $906,000.
• A total of 68.04% of InMode's stock is held by institutional investors and hedge funds, indicating strong institutional interest in the company.
• InMode's stock has shown fluctuations, currently priced at $13.74, with a one-year trading range between $13.14 and $19.85.

Universal Beteiligungs und Servicegesellschaft mbH bought a new position in shares of InMode Ltd. (NASDAQ:INMD - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 51,054 shares of the healthcare company's stock, valued at approximately $906,000. Universal Beteiligungs und Servicegesellschaft mbH owned 0.07% of InMode at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of INMD. CWM LLC grew its position in InMode by 106.4% during the 1st quarter. CWM LLC now owns 2,369 shares of the healthcare company's stock worth $42,000 after acquiring an additional 1,221 shares during the last quarter. GAMMA Investing LLC lifted its position in InMode by 13,923.8% during the 1st quarter. GAMMA Investing LLC now owns 2,945 shares of the healthcare company's stock worth $520,000 after buying an additional 2,924 shares in the last quarter. Orion Capital Management LLC bought a new stake in InMode during the 4th quarter worth about $65,000. Covestor Ltd increased its position in InMode by 13.9% in the 4th quarter. Covestor Ltd now owns 5,936 shares of the healthcare company's stock valued at $99,000 after acquiring an additional 723 shares in the last quarter. Finally, Lazard Asset Management LLC raised its stake in shares of InMode by 6,128.7% in the fourth quarter. Lazard Asset Management LLC now owns 6,291 shares of the healthcare company's stock worth $105,000 after acquiring an additional 6,190 shares during the last quarter. Institutional investors and hedge funds own 68.04% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have issued reports on INMD shares. Barclays reduced their price objective on InMode from $24.00 to $21.00 and set an "overweight" rating on the stock in a report on Wednesday, July 30th. Robert W. Baird lowered InMode from an "outperform" rating to a "neutral" rating and lowered their price objective for the stock from $22.00 to $16.00 in a research report on Monday, April 28th. BTIG Research downgraded shares of InMode from a "buy" rating to a "neutral" rating in a research report on Tuesday, April 29th. Canaccord Genuity Group restated a "hold" rating and issued a $15.00 price objective on shares of InMode in a report on Friday, July 11th. Finally, UBS Group dropped their target price on shares of InMode from $19.00 to $16.25 and set a "neutral" rating for the company in a research report on Tuesday, April 29th. Seven equities research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. According to MarketBeat, InMode presently has a consensus rating of "Hold" and an average price target of $18.04.

InMode Stock Up 1.7%

InMode stock traded up $0.24 during mid-day trading on Tuesday, hitting $14.31. 798,280 shares of the company's stock were exchanged, compared to its average volume of 1,292,849. InMode Ltd. has a fifty-two week low of $13.14 and a fifty-two week high of $19.85. The firm has a market capitalization of $904.52 million, a P/E ratio of 5.77 and a beta of 1.93. The company's 50 day simple moving average is $14.32 and its 200-day simple moving average is $15.94.

InMode (NASDAQ:INMD - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The healthcare company reported $0.47 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.03). InMode had a net margin of 44.50% and a return on equity of 18.38%. The business had revenue of $95.60 million for the quarter, compared to the consensus estimate of $98.45 million. During the same quarter last year, the firm earned $0.34 EPS. The company's revenue for the quarter was up 10.6% on a year-over-year basis. Research analysts expect that InMode Ltd. will post 1.75 EPS for the current year.

InMode Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.